DiogenX announced that it completed a $30 million Series A financing round to support its regenerating insulin-producing beta cells. Marseille, France-based DiogenX aims to use the funds to advance its lead drug candidate into clinical development. The company designed the disease-modifying, recombinant protein to treat patients with type 1 diabetes. It modulates the Wnt/β-catenin signalling […]